17 / 64
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 31, No 6, November/December 2020
AFRICA
297
of Atherosclerosis.
Metabolism
2014;
63
(4): 475–483.
31. Sumner AE, Cowie CC. Ethnic differences in the ability of triglycer-
ide levels to identify insulin resistance.
Atherosclerosis
2008;
196
(2):
696–703.
32. Malan L, Hamer M, von Kanel R, Schlaich MP, Reimann M, Frasure-
Smith N,
et al.
Chronic depression symptoms and salivary NOx are
associated with retinal vascular dysregulation: The SABPA study.
Nitric
Oxide
2016;
55–56
: 10–17.
33. Bessembinders K, Wielders J, van de Wiel A. Severe hypertriglyceridem-
ia influenced by alcohol (SHIBA).
Alcohol Alcohol
2011;
46
(2): 113–116.
34. Jakubik P, Janota T, Widimsky J, Jr, Zelinka T, Strauch B, Petrak O,
et al
. Impact of essential hypertension and primary aldosteronism on
plasma brain natriuretic peptide concentration.
Blood Press
2006;
15
(5):
302–307.
35. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME,
et al
. B-type natriuretic peptide (BNP) and amino-terminal proBNP in
patients with CKD: relationship to renal function and left ventricular
hypertrophy.
Am J Kidney Dis
2005;
46
(4): 610–620.
36. Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriu-
retic hormones (atrial natriuretic peptide, brain natriuretic peptide, and
related peptides) in clinical practice: the need for a new generation of
immunoassay methods.
Clin Chem
2000;
46
(10): 1529–1534.
Trust the
!
Original
S3 ISMO-20 R/7.1.4/136. Isosorbide-5-mononitrate 20 mg/tablet.
For full prescribing information, please refer to package insert.
Pharmaco Distribution (Pty) Ltd. 3 Sandown Valley Crescent, South Tower, 1st Floor, Sandton, 2196; PO Box 786522, Sandton, 2146, South Africa. Tel: + 27 11 784 0077.
Website:
www.pharmaco.co.za1
Long-term prophylaxis and management of
Angina Pectoris
2,3
=
100%
bioavailability
No first-pass metabolism
4
Twice daily
dosage regimen shown
to avoid withdrawal and tolerance
References: 1.
South African approved ISMO package insert.
2.
Ismo 20 Product Monograph (2015).
3.
Abshagen, U., 1992. Pharmacokinetics of isosorbide mononitrate.
The American Journal of Cardiology,
[online] 70(17), pp.G61-G66.
4.
Thadani U, Maranda CR, Amsterdam E, et al. Lack of Pharmacological Tolerance and Rebound
Angina Pectoris during Twice-daily Therapy with Isosorbide-5-Mononitrate.
Annals of Internal Medicine.
1994; 120:353-359. IS_0120.